Home › Funds › Casdin Capital › IPSC
Casdin Capital position in IPSC
CENTURY THERAPEUTICS INC · Health Care
Casdin Capital reported holding 1,228,190 shares of IPSC (CENTURY THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.1M, representing 0.09% of its reported portfolio and ranking #38 among its reported holdings. Casdin Capital has disclosed IPSC holdings in 22 of the last 22 reported quarters, going back to Q2 2021.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Casdin Capital's IPSC position evolved
Casdin Capital first disclosed a stake in IPSC in Q2 2021 at 3,206,380 shares (US$94.1M). Across 22 filings, Casdin Capital increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 16 time(s). The most recent filing (Q3 2026) shows 1,228,190 shares valued at US$2.1M. Notable position changes include a 62% increase in Q2 2024 (shares fell 33% over the following quarter), a 62% increase in Q4 2024 (shares fell 53% over the following quarter), a 62% trim in Q2 2025 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2021 | 3.21M | $94.08M | New |
| Q3 2021 | 3.21M | $80.67M | Hold |
| Q4 2021 | 3.21M | $50.85M | Hold |
| Q1 2022 | 3.21M | $40.37M | Hold |
| Q2 2022 | 3.21M | $26.93M | Hold |
| Q3 2022 | 3.21M | $31.71M | Hold |
| Q4 2022 | 3.21M | $16.45M | Hold |
| Q1 2023 | 3.21M | $11.13M | Hold |
| Q2 2023 | 3.21M | $10.13M | Hold |
| Q3 2023 | 3.21M | $6.41M | Hold |
| Q4 2023 | 3.21M | $10.65M | Hold |
| Q1 2024 | 3.21M | $13.40M | Hold |
| Q2 2024 | 5.19M | $13.24M | Add |
| Q3 2024 | 3.21M | $5.49M | Reduce |
| Q4 2024 | 5.19M | $5.24M | Add |
| Q1 2025 | 3.21M | $1.53M | Reduce |
| Q2 2025 | 1.23M | $686.19K | Reduce |
| Q3 2025 | 1.23M | $611.64K | Hold |
| Q4 2025 | 1.23M | $1.22M | Hold |
| Q1 2026 | 1.23M | $2.78M | Hold |
| Q2 2026 | 1.23M | $3.01M | Hold |
| Q3 2026 | 1.23M | $2.10M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IPSC and 13F data
IPSC (CENTURY THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in IPSC — the largest reported positions include TCG Crossover Management, LLC (US$30.4M), RA CAPITAL MANAGEMENT, L.P. (US$30.4M), Versant Venture Management, LLC (US$20.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IPSC
- TCG Crossover Management, LLC 17.75M sh · $30.36M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 17.75M sh · $30.36M · Q3 2026
- Versant Venture Management, LLC 12.17M sh · $20.80M · Q3 2026
- Commodore Capital LP 8.70M sh · $14.87M · Q3 2026
- Venrock Adviser, LLC 8.70M sh · $14.87M · Q3 2026
- Trails Edge Capital Partners, LP 4.13M sh · $7.07M · Q3 2026
- Spruce Street Capital LP 4.06M sh · $6.94M · Q3 2026
- Seven Fleet Capital Management LP 4.42M sh · $6.08M · Q3 2026
- STEMPOINT CAPITAL LP 2.56M sh · $4.38M · Q3 2026
- DAFNA Capital Management LLC 2.39M sh · $4.08M · Q3 2026
More on Casdin Capital
FAQ
How long has Casdin Capital held IPSC?
Casdin Capital has disclosed IPSC holdings in 22 of the last 22 reported quarters, going back to Q2 2021.
What is Casdin Capital's current position in IPSC?
As of Q3 2026, Casdin Capital holds 1.23M shares of IPSC (CENTURY THERAPEUTICS INC), valued at $2.10M, representing 0.09% of its reported portfolio and ranking #38.
Has Casdin Capital been buying or selling IPSC?
In the latest 13F filing (Q3 2026), Casdin Capital held unchanged its position in IPSC.
Which other funds hold IPSC?
Other major institutional holders of IPSC include TCG Crossover Management, LLC, RA CAPITAL MANAGEMENT, L.P., Versant Venture Management, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.